CEO appointed 2021

Torbjörn holds a BSc BA from IHM Business School. He has experience in leadership and international business development from both larger and smaller companies within Life Science and MedTech, including Novo Nordisk Engineering and Doxa. Experience from First North and IPO.

Holdings in the company: 40,000 shares and 40,000 warrants of series TO1

Erik brings over 25 years of combined experience in financial planning and operations, investor relations, and economic consulting, where he has held financial management positions within i.e. Systembolaget, Aleris, and Coop. He also has background as financial analyst, covering the Nordic medtech and hospital sector at ABG Sundal Collier, among others.

Holdings in the company: 21,233 shares and 151,576 warrants of series TO1

CTO appointed 2021

Jesper holds a MSc Chem and a PhD from Uppsala University. He has experience in product development, scale ups and commercialisation of bio-ceramic products for international markets. Experience from First North and IPO

Holdings in the company: 6,000 shares and 6,000 warrants of series TO1